Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has reached a settlement with Janssen Pharmaceuticals over ORTHO TRI-CYCLEN LO norgestimate/ethinyl estradiol) patent litigation.
Subscribe to our email newsletter
As per the settlement agreement, the companies have signed a supply agreement whereby Janssen will manufacture and supply Watson with an authorized generic version of ORTHO TRI-CYCLEN LO.
Watson will have the right to market and distribute the authorized generic on 31 December 2015 or earlier under certain circumstances. Other details of the settlement were not disclosed.
ORTHO TRI-CYCLEN LO tablets are oral contraceptives indicated for the prevention of pregnancy in women.